Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The role of MYC in the transformation and aggressiveness of 'indolent' B-cell malignancies.
|
31631728 |
2020 |
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Major oncogenic drivers, such as MYC and KRAS proteins are frequently highly overexpressed or mutated in multiple human malignancies.
|
31636382 |
2020 |
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Furthermore, by comparison the expression of proto-oncogene MYC, which is the only well-annotated gene close to the cancer - associated linkage disequilibrium blocks of this region, does not show a pronounced change in expression between the low- and high-grade tumours.
|
30883984 |
2019 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Findings from this study support that CD105 plays a functional role in maintaining cancer stem cell and EMT phenotype, with MYC as a common mediator for both of these traits.
|
31015843 |
2019 |
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Using a variety of cancer cell lines and several technical approaches, including siRNA-mediated gene silencing, ChIP assays, global metabolomics and focused metabolite analyses, bioenergetics, and cell viability assays, we show that two oncogenic Myc proteins, c-Myc and N-Myc, transcriptionally control the expression of the mitochondrial chaperone TNFR-associated protein-1 (TRAP1) in cancer.
|
31097545 |
2019 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Especially, FUBP1 overexpression is observed in a growing number of cancer and leads to a deregulation of targets that includes the fine-tuned MYC oncogene.
|
30343319 |
2019 |
Malignant Neoplasms
|
0.600 |
PosttranslationalModification
|
group |
BEFREE |
Integrative methylome and transcriptome analyses showed that a massive downregulation of genes, including oncogenes (e.g., MYC) and epigenetic modifiers (e.g., KDM2B, SUV39H1) often overexpressed in cancer, was associated predominantly with gene body DNA demethylation and changes in acH3K9/27.
|
30470836 |
2019 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Aberrant MYC oncogene activation is one of the most prevalent characteristics of cancer.
|
31262815 |
2019 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Emerging Roles of C-Myc in Cancer Stem Cell-Related Signaling and Resistance to Cancer Chemotherapy: A Potential Therapeutic Target Against Colorectal Cancer.
|
31083525 |
2019 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
MYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance.
|
31341534 |
2019 |
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
c-MYC empowers transcription and productive splicing of the oncogenic splicing factor Sam68 in cancer.
|
31066450 |
2019 |
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
MYC is an oncoprotein that coordinates the expression of genes involved in metabolism, cell differentiation and survival in various types of malignancies.
|
31357093 |
2019 |
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
These data indicated that in addition to EBNA2, TAF family members and MEF2C are essential for ESE activity, MYC expression, and LCL growth.<b>IMPORTANCE</b> SEs play critical roles in cancer development.
|
31167905 |
2019 |
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Overexpression of MYC oncogene is highly prevalent in many malignancies such as aggressive triple-negative breast cancers (TNBCs) and it is associated with very poor outcome.
|
30076412 |
2019 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
SIGNIFICANCE: Competitive chemical inhibition of the PA2G4-MYCN protein interface provides a basis for drug design of small molecules targeting MYC and MYCN-binding partners in malignancies driven by MYC family oncoproteins.
|
31501192 |
2019 |
Malignant Neoplasms
|
0.600 |
PosttranslationalModification
|
group |
BEFREE |
Our data may show a common underlying epigenetic dysregulation in cancer associated with broad enrichment of repressive chromatin marks and aberrant DNA hypermethylation at TSSs in combination with MYC network activation.
|
31097695 |
2019 |
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Individuals infected with human immunodeficiency virus (HIV) are at increased risk for Burkitt lymphoma, a B-cell malignancy which occurs after a chromosomal translocation rearranging the MYC oncogene with an immunoglobulin gene locus, usually the IGH heavy chain gene locus.
|
30701532 |
2019 |
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
These include targeting the deregulation of MYC transcription in cancer through small-molecule inhibitors that induce epigenetic silencing or that regulate the G-quadruplex structures within the MYC promoter.
|
31392631 |
2019 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Genomic amplification of HPV, h-TERC and c-MYC in liquid-based cytological specimens for screening of cervical intraepithelial neoplasia and cancer.
|
30675277 |
2019 |
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Increased expression of the oncogene MYC is a common feature of many B-cell malignancies, however MYC overexpression by itself is not sufficient for transformation, and additional genetic events are required, although the exact nature of these remains unknown.
|
30281155 |
2019 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The bromodomain and extra-terminal (BET) proteins play significant roles in supporting the transcription of known DLBCL oncogene MYC, which provides a way for the development of targeted therapeutic agents to address this kind of malignant tumor.
|
31527063 |
2019 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer.
|
28466200 |
2019 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
How MYC regulates the metabolism of other amino acids in cancer is not fully understood.
|
31416966 |
2019 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The dependence of MYC on cofactors creates opportunities for therapeutic intervention, but for any cofactor this requires structural understanding of how the cofactor interacts with MYC, knowledge of the role it plays in MYC function, and demonstration that disrupting the cofactor interaction will cause existing cancers to regress.
|
31767764 |
2019 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The MYC:TRRAP interaction is critical for MYC function in promoting cancer.
|
31790487 |
2019 |